While a significant number of uveitis drugs are already in the pipeline, increasing in-licensing approvals for new market entrants will boost the scope of treatment against uveitis, ultimately creating new lucrative opportunities,” states Persistence Market Research. Increasing demand for generic drugs also prompt at an important trend in the global uveitis treatment market that will reportedly generate a range of opportunities for established as well as new pharma players. In addition to growing R&D activities in the field of eye disorders, rising optometric clinical practice will also provide an impetus to market growth. With surging uveitis prevalence, a host of biological drug development projects is anticipated to push the potential of the uveitis treatment market. Moreover, growing prevalence of TB associated with intermediate uveitis will continue to push the opportunities in intermediate uveitis segment. no dataAnother proliferating trend in uveitis treatment market includes increasing demand for local steroid implants, especially for non-infectious posterior uveitis. As corticosteroid mono-therapy is no more considered the first line treatment for uveitis, the market has been witnessing introduction of various modified corticosteroid medication and drug delivery methods since the recent past. Reading For Hours Together, Working On The Computer For A Long Time, Etc., Are The Significant Causes Of Strain. | Advice To The ViewMajor players in the segment are working to add novel drugs to their product portfolio. R&D in topical agents segment will also benefit the market growth in near future.
For the original version including any supplementary images or video, visit https://www.thestreet.com/story/13950063/1/global-uveitis-treatment-market-revenues-poised-to-reach-us-8478-mn-by-2024–persistence-market-research.html